This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

SCID with Low or Normal B-cell NumbersB-세포수가 정상이거나 감소된 중증복합면역결핍

ICD-10: D81.2 | Synonyms: T-B+NK- SCID, T-B+NK+ SCID, γc-SCID, JAK3 deficiency SCID, IL-7Rα deficiency SCID, X-linked severe combined immunodeficiency (X-SCID)

Contents
  1. History
  2. Causes
  3. Genetics
  4. General epidemiology
  5. Pathophysiology
  6. Symptoms
  7. Signs
  8. Screening
  9. Diagnosis
  10. Treatment
  11. Prognosis
  12. Prevention
  13. References

1. History

First description and X-linked SCID

Forms of SCID in which B cells are normal or elevated despite T-cell deficiency were already recognized clinically in the 1960s–70s. In particular, attention was drawn to the fact that SCID showing an X-linked mode of inheritance occurs only in boys, and this was named X-linked severe combined immunodeficiency (X-SCID).

Discovery of the IL-2Rγ (γc) gene

In 1993, Noguchi et al. showed that X-SCID is caused by mutations in the interleukin-2 receptor gamma chain (IL2RG, γc) gene located on the X chromosome. It was subsequently established that γc is the common gamma chain of the IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21 receptors and is essential for signaling by multiple cytokines.

Discovery of JAK3 and IL-7Rα deficiency

In 1995, Macchi et al. reported that JAK3 deficiency, a kinase linked to γc, causes autosomal recessive SCID. In the same year, Puel et al. discovered that IL-7Rα (IL7R gene) deficiency causes T-B+NK+ SCID.

History of gene therapy

In 2000, Fischer's team succeeded in γc gene therapy using a retroviral vector in X-SCID patients, reporting the world's first successful clinical case of gene therapy. However, T-cell leukemia due to insertional mutagenesis subsequently developed in some patients, raising major challenges regarding vector safety.

2. Causes

IL2RG defect (X-SCID)

Mutations in the IL2RG gene (Xq13.1) located on the X chromosome are the most common cause, accounting for about 40–50% of all SCID. The γc protein functions as the common gamma chain of the IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21 receptors.

JAK3 defect

Mutations in the JAK3 gene (19p13.1) are inherited in an autosomal recessive manner and show a T-B+NK- phenotype similar to γc. JAK3 binds to γc and transmits cytokine signals to the JAK-STAT pathway.

IL7R defect

IL-7Rα (IL7R gene, 5p13.2) deficiency causes T-B+NK+ SCID. IL-7 is essential for T-cell development, but IL-15 is more important for NK-cell development, so NK cells are preserved.

Other causes

Various causes, such as defects in CD45 (PTPRC), CD3δ, CD3ε, CD3ζ, and CD3γ, can cause SCID with a T-B+ phenotype.

3. Genetics

X-linked mode of inheritance (X-SCID)

X-SCID due to IL2RG mutations follows X-linked recessive inheritance. When the mother is a carrier, 50% of sons are affected. Female heterozygous carriers are normal, but very rarely symptoms may appear when there is skewed X-inactivation.

Autosomal recessive inheritance (JAK3, IL7R defects)

JAK3 and IL7R defects are autosomal recessive and affect males and females equally.

Phenotypic spectrum

Partial loss-of-function variants of IL2RG can show various phenotypes milder than complete SCID, such as combined immunodeficiency (CID), Omenn syndrome, and DiGeorge-like syndrome.

4. General epidemiology

Worldwide prevalence

D81.2 (T-B+NK+ or T-B+NK- SCID) includes the most common types of all SCID. X-SCID alone accounts for about 40–50% of all SCID. The overall incidence of SCID is 1/50,000–1/100,000 newborns.

Sex ratio

Because X-SCID occurs only in boys, in populations where X-SCID predominates, the proportion of boys among all SCID patients is high (about 2:1–3:1). JAK3 and IL7R defects occur equally in males and females.

Status in Korea

In Korea, T-B+ types of SCID, including X-SCID, are reported under the D81.2 classification. There are a small number of confirmed cases at tertiary medical institutions such as Seoul National University Children's Hospital, and accurate national data are lacking.

5. Pathophysiology

Impairment of the γc-JAK3 signaling pathway

γc is the common signaling subunit of the IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21 receptors. γc binds JAK3 and, upon cytokine binding, activates the JAK-STAT signaling pathway, which activates transcription factors such as STAT5 and STAT3. In γc or JAK3 deficiency, signaling by all of these cytokines is blocked.

Block in T-cell and NK-cell development

Blockade of IL-7 signaling makes proliferation and survival of T progenitor cells in the thymus impossible, so T-cell development is almost completely blocked. Blockade of IL-15 signaling also blocks NK-cell development (γc/JAK3 defects with the T-B+NK- phenotype). In IL-7Rα deficiency, only IL-7 signaling is blocked, so T cells are deficient but NK cells develop normally via IL-15 signaling (T-B+NK+ phenotype).

B-cell dysfunction

Because B cells have no direct impairment of V(D)J recombination, they are present in normal or increased numbers, but they cannot mount functional antibody responses owing to the lack of T-cell help.

6. Symptoms

Typical SCID symptoms

After 3–6 months of age, pneumonia, chronic diarrhea, oral candidiasis, skin infections, sepsis, etc. recur. Disseminated BCG infection after BCG vaccination may occur and can provide a clue to the diagnosis. Pneumocystis jirovecii pneumonia (PCP) is frequent and fatal.

Growth and developmental delay

Weight loss, failure to thrive, and developmental delay due to recurrent infections accompany.

Characteristic symptoms

In some patients, engraftment of maternal T cells in the fetus during pregnancy (maternal-fetal graft-versus-host reaction) can cause skin rash, liver function abnormalities, and cytopenias.

7. Signs

Physical examination

Underdeveloped tonsils, nonpalpable lymph nodes, absent thymic shadow on chest radiography. Findings of severe failure to thrive and malnutrition are common.

Hematologic and immunologic findings

CBC shows a decreased absolute lymphocyte count (especially decreased T cells). Flow cytometry shows markedly decreased T cells (CD3+), normal or increased B cells (CD19+), and decreased NK cells (γc/JAK3 defects) or normal NK cells (IL7R defect). Serum IgG, IgA, and IgM are decreased (after 6 months of age).

T-cell function tests

T-cell proliferative responses to mitogens such as PHA and ConA are markedly reduced or absent.

8. Screening

TREC-based newborn screening

Because of T-cell deficiency, TRECs are extremely low or undetectable. Both X-SCID and JAK3/IL7R deficiency SCID show a positive result on TREC screening.

Prenatal screening for X-linked SCID

When there is a family history, prenatal diagnosis is made during pregnancy by maternal serum genetic testing (cell-free DNA) or by IL2RG gene analysis after CVS/amniocentesis.

9. Diagnosis

Phenotypic classification

Flow cytometry confirms a T-B+NK- or T-B+NK+ phenotype. T-B+NK- phenotype → suspect IL2RG or JAK3 defect. T-B+NK+ phenotype → suspect IL7R, CD3 chain, or CD45 defect.

Genetic confirmation

IL2RG sequencing (confirmation of X-SCID), JAK3 and IL7R gene analysis. If the standard gene panel is negative, whole exome sequencing (WES) is performed.

Confirmation of γc protein expression

Confirming loss of γc (CD132) protein expression by Western blot or flow cytometry aids rapid diagnosis.

10. Treatment

Hematopoietic stem cell transplantation (HSCT)

HSCT is the standard curative treatment. With early transplantation (before 3.5 months of age, in an infection-free state), a survival rate of 90% or more can be expected. In X-SCID, T-cell and NK-cell reconstitution after HSCT is excellent, but when B-cell reconstitution is incomplete, long-term IVIG is needed.

Gene therapy

X-SCID is one of the most successful models of gene therapy. Clinical trials of IL2RG gene therapy using self-inactivating (SIN) lentiviral vectors are under way in the United States (UCSF), the United Kingdom (UCL), France (Paris), and elsewhere, and early results are promising.

Supportive care

Protective isolation, IVIG, antibacterial·antifungal·antiviral prophylaxis. No BCG vaccination, no live vaccines. Use of CMV-negative irradiated blood.

11. Prognosis

Prognosis with early transplantation

In patients who underwent HSCT before infections occurred through newborn screening, survival at 10 years or more exceeds 90%. When infections are present, the prognosis is markedly poor.

Prognosis with gene therapy

In clinical trials of SIN lentiviral gene therapy, 90% or more of patients showed T-cell reconstitution and clinical improvement.

Long-term complications

Incomplete immune reconstitution after HSCT, chronic graft-versus-host disease (cGvHD), growth problems, etc. are issues for long-term follow-up.

12. Prevention

Expansion of newborn screening

Nationwide expansion of TREC-based newborn screening aims at early diagnosis and HSCT before infections occur.

Prenatal management of X-SCID families

In high-risk pregnancies with a family history, prenatal genetic diagnosis and planning of HSCT before delivery are important.

Infection prevention

No live vaccines (BCG, MMR, varicella, etc.), PCP prophylaxis, IVIG supplementation, protective isolation. In families with a sibling with SCID, the newborn is isolated immediately and genetic testing is performed.

13. References

  1. Noguchi M, Yi H, Rosenblatt HM, et al. Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans. Cell. 1993;73(1):147-157.
  2. Macchi P, Villa A, Giliani S, et al. Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature. 1995;377(6544):65-68.
  3. Puel A, Ziegler SF, Buckley RH, Leonard WJ. Defective IL7R expression in T(-)B(+)NK(+) severe combined immunodeficiency. Nat Genet. 1998;20(4):394-397.
  4. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science. 2000;288(5466):669-672.
  5. Hacein-Bey-Abina S, Hauer J, Lim A, et al. Efficacy of gene therapy for X-linked severe combined immunodeficiency. N Engl J Med. 2010;363(4):355-364.
  6. Pai SY, Logan BR, Griffith LM, et al. Transplantation outcomes for severe combined immunodeficiency, 2000-2009. N Engl J Med. 2014;371(5):434-446.
  7. Kwan A, Abraham RS, Currier R, et al. Newborn screening for severe combined immunodeficiency in 11 screening programs in the United States. JAMA. 2014;312(7):729-738.
  8. Fischer A, Notarangelo LD, Neven B, Cavazzana M, Puck JM. Severe combined immunodeficiencies and related disorders. Nat Rev Dis Primers. 2015;1:15061.
  9. Buckley RH. Molecular defects in human severe combined immunodeficiency and approaches to immune reconstitution. Annu Rev Immunol. 2004;22:625-655.
  10. De Ravin SS, Wu X, Moir S, et al. Lentiviral hematopoietic stem cell gene therapy for X-linked severe combined immunodeficiency. Sci Transl Med. 2016;8(335):335ra57.
  11. Gaspar HB, Qasim W, Davies EG, et al. How I treat severe combined immunodeficiency. Blood. 2013;122(23):3749-3758.
  12. Lee WI, Kang JH, Kim JM, et al. Clinical and laboratory features of Korean children with primary immunodeficiency disorders. J Korean Med Sci. 2013;28(11):1553-1560.